DrugBank ID Drug Name Target ID Gene Symbol UniProt ID UniProt Entry Regulation Type PubMed IDs Citations Groups Direct Classification Detailed Classification Categories SMILES PubChem ID Pathways Pathway Sources KEGG Pathway IDs DPD PubChem Substance KEGG Drug PharmGKB UniProtKB TTD Wikipedia ChEMBL RxCUI DB00039 Palifermin BE0000748 FGFR2 P21802 FGFR2_HUMAN agonist 17728847; 16390600; 16854582; 7499435; 9056643; 10593896; 17456767; 11752352; 8663044 "Beaven AW, Shea TC: Recombinant human keratinocyte growth factor palifermin reduces oral mucositis and improves patient outcomes after stem cell transplant. Drugs Today (Barc). 2007 Jul;43(7):461-73.@@Radtke ML, Kolesar JM: Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J Oncol Pharm Pract. 2005 Sep;11(3):121-5.@@Huang YW, Wang LS, Chang HL, Ye W, Shu S, Sugimoto Y, Lin YC: Effect of keratinocyte growth factor on cell viability in primary cultured human prostate cancer stromal cells. J Steroid Biochem Mol Biol. 2006 Jul;100(1-3):24-33. Epub 2006 Jul 18.@@Patrie KM, Kudla AJ, Olwin BB, Chiu IM: Conservation of ligand specificity between the mammalian and amphibian fibroblast growth factor receptors. J Biol Chem. 1995 Dec 1;270(48):29018-24.@@Cardoso WV, Itoh A, Nogawa H, Mason I, Brody JS: FGF-1 and FGF-7 induce distinct patterns of growth and differentiation in embryonic lung epithelium. Dev Dyn. 1997 Mar;208(3):398-405.@@Berman B, Ostrovsky O, Shlissel M, Lang T, Regan D, Vlodavsky I, Ishai-Michaeli R, Ron D: Similarities and differences between the effects of heparin and glypican-1 on the bioactivity of acidic fibroblast growth factor and the keratinocyte growth factor. J Biol Chem. 1999 Dec 17;274(51):36132-8.@@Zhu X, Lee K, Asa SL, Ezzat S: Epigenetic silencing through DNA and histone methylation of fibroblast growth factor receptor 2 in neoplastic pituitary cells. Am J Pathol. 2007 May;170(5):1618-28.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Ornitz DM, Xu J, Colvin JS, McEwen DG, MacArthur CA, Coulier F, Gao G, Goldfarb M: Receptor specificity of the fibroblast growth factor family. J Biol Chem. 1996 Jun 21;271(25):15292-7." Approved Peptides "Organic Compounds; Organic Acids; Carboxylic Acids and Derivatives; Amino Acids, Peptides, and Analogues" "Biological Factors; Intercellular Signaling Peptides and Proteins; Peptides; Proteins; Detoxifying Agents for Antineoplastic Treatment; Fibroblast Growth Factors; Mucocutaneous Epithelial Cell Growth Factor; Amino Acids, Peptides, and Proteins; Increased Epithelial Proliferation" 17147 46506691 PA164744014 P21781 DAP001026 Palifermin CHEMBL1201821 196319 DB00113 Technetium Tc-99m arcitumomab BE0000107 CEACAM1 P13688 CEAM1_HUMAN other/unknown 12865871; 9389396 "Fuster D, Maurel J, Muxi A, Setoain X, Ayuso C, Martin F, Ortega ML, Fuertes S, Pons F: Is there a role for (99m)Tc-anti-CEA monoclonal antibody imaging in the diagnosis of recurrent colorectal carcinoma? Q J Nucl Med. 2003 Jun;47(2):109-15.@@Hughes K, Pinsky CM, Petrelli NJ, Moffat FL, Patt YZ, Hammershaimb L, Goldenberg DM: Use of carcinoembryonic antigen radioimmunodetection and computed tomography for predicting the resectability of recurrent colorectal cancer. Ann Surg. 1997 Nov;226(5):621-31." Experimental Peptides "Organic Compounds; Organic Acids; Carboxylic Acids and Derivatives; Amino Acids, Peptides, and Analogues" "Antibodies; Diagnostic Radiopharmaceuticals; Immunoglobulins; Organometallic Compounds; Serum Globulins; Technetium (99Mtc) Compounds; Immunoproteins; Tumour Detection; Proteins; Globulins; Blood Proteins; Amino Acids, Peptides, and Proteins" 46507781 PA164746540 DAP001303 Arcitumomab CHEMBL2108253 230435 DB00230 Pregabalin BE0000691 CACNA2D1 P54289 CA2D1_HUMAN 24533015 "Verma V, Singh N, Singh Jaggi A: Pregabalin in neuropathic pain: evidences and possible mechanisms. Curr Neuropharmacol. 2014 Jan;12(1):44-56. doi: 10.2174/1570159X1201140117162802." Approved; Investigational Gamma amino acids and derivatives "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" "Sensory System Agents; QTc Prolonging Agents; Agents causing angioedema; Amino Acids, Peptides, and Proteins; Butyrates; Muscle Relaxants, Centrally Acting Agents; Miscellaneous Anticonvulsants; Central Nervous System Depressants; Muscle Relaxants; Drugs that are Mainly Renally Excreted; Membrane Transport Modulators; Potential QTc-Prolonging Agents; Amino Acids; Vasodilating Agents; Acids, Acyclic; Peripheral Nervous System Agents; Analgesics; Aminobutyrates; Anti-Anxiety Agents; Psychotropic Drugs; Central Nervous System Agents; Tranquilizing Agents; Hypoglycemia-Associated Agents; Bradycardia-Causing Agents; Nervous System; Anticonvulsants; Gabapentinoids" CC(C)C[C@H](CN)CC(O)=O 15568 46504934 D02716 PA164754814 DAP001264 Pregabalin CHEMBL1059 187832 DB00252 Phenytoin BE0008715 CACNA1C O00555 CAC1A_HUMAN inhibitor 28349209 Keppel Hesselink JM: Phenytoin: a step by step insight into its multiple mechanisms of action-80 years of mechanistic studies in neuropharmacology. J Neurol. 2017 Sep;264(9):2043-2047. doi: 10.1007/s00415-017-8465-4. Epub 2017 Mar 27. Approved; Vet_approved Phenylhydantoins Organic compounds; Organoheterocyclic compounds; Azolidines; Imidazolidines Cytochrome P-450 CYP2B6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inducers (strong); Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C18 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2B6 Inducers; Agents Causing Muscle Toxicity; Cytochrome P-450 CYP1A2 Inducers (strength unknown); Cytochrome P-450 CYP2C8 Inducers; Cytochrome P-450 CYP3A5 Substrates; Thyroxine-binding globulin substrates; Cytochrome P-450 CYP2A6 Substrates; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP2A6 Substrates with a Narrow Therapeutic Index; Methemoglobinemia Associated Agents; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Cytochrome P-450 CYP2C19 Inducers; Cytochrome P-450 CYP2C9 Substrates; Imidazolidines; UGT1A4 substrates; Cytochrome P-450 CYP3A Inducers; Narrow Therapeutic Index Drugs; Anticonvulsants; Cytochrome P-450 CYP2B6 Inducers (strong); Phenytoin and Prodrugs; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP3A5 Inducers; P-glycoprotein substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP3A7 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Substrates; UGT1A6 substrate; Sodium Channel Blockers; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A Inducers (strong); UGT1A9 Inhibitors; Imidazoles; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Enzyme Inducing Antiepileptic Drugs; P-glycoprotein substrates; Cytochrome P-450 CYP2C19 Substrates; Cytochrome P-450 CYP3A7 Inducers (weak); COMT Substrates; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; UGT1A9 Substrates; Nervous System; Anti-epileptic Agent; Cytochrome P-450 CYP2C9 Inducers; Decreased Central Nervous System Disorganized Electrical Activity; UGT1A1 Inducers; UGT1A6 Inhibitors; Hyperglycemia-Associated Agents; Cytochrome P-450 CYP2C19 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A7 Inducers; Cytochrome P-450 CYP2C8 Substrates; Central Nervous System Depressants; Cytochrome P-450 Substrates; UGT1A1 Substrates with a Narrow Therapeutic Index; UGT1A9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; Membrane Transport Modulators; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP2E1 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 Inducers (moderate); Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers (strong); UGT1A6 Substrates with a Narrow Therapeutic Index; Voltage-Gated Sodium Channel Blockers; Hydantoins; Central Nervous System Agents; UGT1A1 Substrates; Inducers of Drug Clearance; Cytochrome P-450 CYP3A5 Inducers (strength unknown) O=C1NC(=O)C(N1)(C1=CC=CC=C1)C1=CC=CC=C1 Fosphenytoin (Antiarrhythmic) Action Pathway; Fosphenytoin (Antiarrhythmic) Metabolism Pathway; Phenytoin (Antiarrhythmic) Action Pathway drug_metabolism; drug_action 10209 46508847 D00512 PA450947 DAP000130 Phenytoin CHEMBL16 8183 DB00270 Isradipine BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 17016423; 17139284; 11752352 "Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5." Approved; Investigational Benzoxadiazoles Organic compounds; Organoheterocyclic compounds; Benzoxadiazoles QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Drugs that are Mainly Renally Excreted; Membrane Transport Modulators; Cytochrome P-450 CYP3A4 Inhibitors; Calcium Channel Blockers (Dihydropyridine); P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; BSEP/ABCB11 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC2=NON=C12)C(=O)OC(C)C Isradipine Action Pathway drug_action 46505034 D00349 PA450131 DAP000134 Isradipine CHEMBL1648 33910 DB00308 Ibutilide BE0000691 CACNA2D1 P54289 CA2D1_HUMAN activator 15926871; 9257085 "Doggrell SA, Hancox JC: Ibutilide--recent molecular insights and accumulating evidence for use in atrial flutter and fibrillation. Expert Opin Investig Drugs. 2005 May;14(5):655-69.@@Foster RH, Wilde MI, Markham A: Ibutilide. A review of its pharmacological properties and clinical potential in the acute management of atrial flutter and fibrillation. Drugs. 1997 Aug;54(2):312-30." Approved Phenylbutylamines Organic compounds; Benzenoids; Benzene and substituted derivatives; Phenylbutylamines "Antiarrhythmic agents; Cardiovascular Agents; QTc Prolonging Agents; Sulfones; Cardiac Therapy; Highest Risk QTc-Prolonging Agents; Sulfur Compounds; Amides; Drugs that are Mainly Renally Excreted; Antiarrhythmics, Class III" CCCCCCCN(CC)CCCC(O)C1=CC=C(NS(C)(=O)=O)C=C1 Ibutilide Action Pathway drug_action 12005 46507904 D00648 PA449958 DAP000279 Ibutilide CHEMBL533 41289 DB00337 Pimecrolimus BE0000695 FKBP1A P62942 FKB1A_HUMAN potentiator 12113647 "Reitamo S, Remitz A, Kyllonen H, Saarikko J: Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol. 2002;3(6):381-8." Approved; Investigational Macrolide lactams Organic compounds; Phenylpropanoids and polyketides; Macrolide lactams "Calcineurin Inhibitor Immunosuppressant; Sensory System Agents; Enzyme Inhibitors; Anti-Inflammatory Agents; Cytochrome P-450 CYP3A Substrates; Peptidylprolyl Isomerase, antagonists & inhibitors; Dermatologicals; Cytochrome P-450 Substrates; Immunologic Factors; Misc. Skin and Mucous Membrane Agents; Analgesics, Non-Narcotic; Lactones; Cytochrome P-450 CYP3A4 Substrates; Peripheral Nervous System Agents; Analgesics; Immunosuppressive Agents; Agents for Dermatitis, Excluding Corticosteroids; Calcineurin Inhibitors" [H][C@]1(CC[C@H](Cl)[C@@H](C1)OC)\C=C(/C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC)C(=O)C[C@H](O)[C@H]1C)OC 12077 46505748 PA164783790 DAP000594 Pimecrolimus CHEMBL1200686 321952 DB00401 Nisoldipine BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 11752352 "Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5." Approved Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Calcium Channel Blockers; Photosensitizing Agents; Drugs that are Mainly Renally Excreted; Membrane Transport Modulators; Calcium Channel Blockers (Dihydropyridine); P-glycoprotein inhibitors; Cytochrome P-450 CYP3A5 Substrates; Decreased Blood Pressure; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Drugs causing inadvertant photosensitivity; Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A7 Substrates COC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1[N+]([O-])=O)C(=O)OCC(C)C Nisoldipine Action Pathway drug_action 46504546 D00618 PA450634 DAP000595 Nisoldipine CHEMBL1726 7435 DB00421 Spironolactone BE0008715 CACNA1C O00555 CAC1A_HUMAN inhibitor 10942165; 3427267; 2162139 "Sorrentino R, Autore G, Cirino G, d'Emmanuele de Villa Bianca R, Calignano A, Vanasia M, Alfieri C, Sorrentino L, Pinto A: Effect of spironolactone and its metabolites on contractile property of isolated rat aorta rings. J Cardiovasc Pharmacol. 2000 Aug;36(2):230-5.@@Dacquet C, Loirand G, Mironneau C, Mironneau J, Pacaud P: Spironolactone inhibition of contraction and calcium channels in rat portal vein. Br J Pharmacol. 1987 Nov;92(3):535-44. doi: 10.1111/j.1476-5381.1987.tb11354.x.@@Mironneau J: Calcium channel antagonist effects of spironolactone, an aldosterone antagonist. Am J Cardiol. 1990 Jun 19;65(23):7K-8K; discussion 3K. doi: 10.1016/0002-9149(90)91267-a." Approved Spironolactones and derivatives Organic compounds; Lipids and lipid-like molecules; Steroids and steroid derivatives; Steroid lactones "Cytochrome P-450 CYP2C8 Inhibitors (moderate); Mineralocorticoid (Aldosterone) Receptor Antagonists; Pregnenes; Antihypertensive Agents; P-glycoprotein inducers; Hormone Antagonists; Mineralocorticoid Receptor Antagonists; Hypotensive Agents; Cytochrome P-450 CYP2C8 Inhibitors; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Steroids; Fused-Ring Compounds; Potassium-Sparing Diuretics; Diuretics; Lactones; BSEP/ABCB11 Substrates; Natriuretic Agents; Pregnanes; Hormones, Hormone Substitutes, and Hormone Antagonists" [H][C@@]12CC[C@@]3(CCC(=O)O3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])[C@@]([H])(CC2=CC(=O)CC[C@]12C)SC(C)=O Spironolactone Action Pathway drug_action 7408 46508525 D00443 PA451483 DAP000297 Spironolactone CHEMBL1393 9997 DB00622 Nicardipine BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 11752352 "Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5." Approved; Investigational Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2D6 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; QTc Prolonging Agents; Cytochrome P-450 CYP2C9 Inhibitors (strong); Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Selective Calcium Channel Blockers With Mainly Vascular Effects; Adrenergic alpha-Antagonists; Agents producing tachycardia; Cytochrome P-450 CYP3A5 Inhibitors; Dihydropyridine Derivatives; Pyridines; Cytochrome P-450 CYP2C8 Substrates; Hypotensive Agents; Cytochrome P-450 CYP2C8 Inhibitors; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Membrane Transport Modulators; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP2B6 Inducers; Calcium Channel Blockers (Dihydropyridine); P-glycoprotein inhibitors; Cytochrome P-450 CYP2E1 Substrates; Anticholinergic Agents; Potential QTc-Prolonging Agents; Adrenergic Antagonists; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); BSEP/ABCB11 Substrates; Antiarrhythmic agents; Cytochrome P-450 CYP2B6 Inducers (strength unknown); Muscarinic Antagonists; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Bradycardia-Causing Agents COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OCCN(C)CC1=CC=CC=C1 1293 46504482 PA450620 DAP000486 Nicardipine CHEMBL1484 7396 DB00653 Magnesium sulfate BE0008715 CACNA1C O00555 CAC1A_HUMAN inhibitor 16157690; 11300616; 8410712; 26422671; 19933511 "Brunet S, Scheuer T, Klevit R, Catterall WA: Modulation of CaV1.2 channels by Mg2+ acting at an EF-hand motif in the COOH-terminal domain. J Gen Physiol. 2005 Oct;126(4):311-23. doi: 10.1085/jgp.200509333. Epub 2005 Sep 12.@@Bara M, Guiet-Bara A: Magnesium regulation of Ca2+ channels in smooth muscle and endothelial cells of human allantochorial placental vessels. Magnes Res. 2001 Mar;14(1-2):11-8.@@Kuo CC, Hess P: Block of the L-type Ca2+ channel pore by external and internal Mg2+ in rat phaeochromocytoma cells. J Physiol. 1993 Jul;466:683-706.@@Zhao M, Feng R, Shao D, Liu S, Lei M, Wang H, Sun X, Guo F, Hu H, Kameyama M, Hao L: Mg(2+)-dependent facilitation and inactivation of L-type Ca(2+) channels in guinea pig ventricular myocytes. J Pharmacol Sci. 2015 Nov;129(3):143-9. doi: 10.1016/j.jphs.2015.08.001. Epub 2015 Aug 7.@@Lin CY, Tsai PS, Hung YC, Huang CJ: L-type calcium channels are involved in mediating the anti-inflammatory effects of magnesium sulphate. Br J Anaesth. 2010 Jan;104(1):44-51. doi: 10.1093/bja/aep336." Approved; Investigational; Vet_approved Alkaline earth metal sulfates Inorganic compounds; Mixed metal/non-metal compounds; Alkaline earth metal oxoanionic compounds; Alkaline earth metal sulfates "Blood Substitutes and Perfusion Solutions; Sensory System Agents; Agents that produce neuromuscular block (indirect); Magnesium Salts; Dermatologicals; Electrolyte Solutions; Tocolytic Agents; Metal cations; Tests for Bile Duct Patency; Miscellaneous Anticonvulsants; Cardiovascular Agents; I.V. Solution Additives; Osmotic Laxatives; Central Nervous System Depressants; Agents causing hyperkalemia; Mineral Supplements; Calcium Channel Blockers; Anesthetics; Membrane Transport Modulators; Alimentary Tract and Metabolism; Laxatives, magnesium containing; Diagnostic Agents; Replacement Preparations; Blood and Blood Forming Organs; Magnesium Compounds; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Sulfur Acids; Peripheral Nervous System Agents; Analgesics; Antiarrhythmic agents; Central Nervous System Agents; Metal divalent cations; Laxatives; Sulfates; Bradycardia-Causing Agents; Sulfur Compounds; Sulfuric Acids; Anticonvulsants; Reproductive Control Agents; Drugs for Constipation" [Mg++].[O-]S([O-])(=O)=O 6487 46508411 D01108 PA450302 DAP000201 Magnesium_sulfate CHEMBL2021423 1311625 DB00661 Verapamil BE0000356 CACNA1A O00555 CAC1A_HUMAN inhibitor 10385261 "Dobrev D, Milde AS, Andreas K, Ravens U: The effects of verapamil and diltiazem on N-, P- and Q-type calcium channels mediating dopamine release in rat striatum. Br J Pharmacol. 1999 May;127(2):576-82. doi: 10.1038/sj.bjp.0702574." Approved Phenylbutylamines Organic compounds; Benzenoids; Benzene and substituted derivatives; Phenylbutylamines OATP1B1/SLCO1B1 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Amines; Miscellaneous Calcium-channel Blocking Agents; Adrenergic alpha-1 Receptor Antagonists; Antihypertensive Agents; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Adrenergic alpha-Antagonists; Phenylalkylamine Derivatives; Cytochrome P-450 CYP3A5 Inhibitors; MATE 1 Inhibitors; Cytochrome P-450 CYP2C8 Substrates; Hypotensive Agents; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 CYP2B6 Substrates; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; ACE Inhibitors and Calcium Channel Blockers; OCT1 substrates; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Drugs that are Mainly Renally Excreted; Negative Inotrope; P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Membrane Transport Modulators; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP2C19 Substrates; P-glycoprotein inhibitors; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP3A5 Substrates; Adrenergic Antagonists; Cytochrome P-450 CYP2C9 Inhibitors (weak); Vasodilating Agents; MATE inhibitors; Verapamil and analogues; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP2C18 Substrates; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Antiarrhythmic agents; Calcium Channel Blockers (Nondihydropyridine); Cytochrome P-450 CYP3A5 Inhibitors (moderate); Cytochrome P-450 CYP2C9 Substrates; MATE 2 Inhibitors; OCT1 inhibitors; Bradycardia-Causing Agents; Selective Calcium Channel Blockers With Direct Cardiac Effects; Cytochrome P-450 CYP1A2 Substrates COC1=C(OC)C=C(CCN(C)CCCC(C#N)(C(C)C)C2=CC(OC)=C(OC)C=C2)C=C1 Verapamil Action Pathway drug_action 10110 46508158 D02356 PA451868 DAP000040 Verapamil CHEMBL6966 11170 DB00825 Levomenthol BE0008715 CACNA1C O00555 CAC1A_HUMAN antagonist 16121523; 2856502 "Grigoleit HG, Grigoleit P: Pharmacology and preclinical pharmacokinetics of peppermint oil. Phytomedicine. 2005 Aug;12(8):612-6. doi: 10.1016/j.phymed.2004.10.007.@@Hawthorn M, Ferrante J, Luchowski E, Rutledge A, Wei XY, Triggle DJ: The actions of peppermint oil and menthol on calcium channel dependent processes in intestinal, neuronal and cardiac preparations. Aliment Pharmacol Ther. 1988 Apr;2(2):101-18." Approved Menthane monoterpenoids Organic compounds; Lipids and lipid-like molecules; Prenol lipids; Monoterpenoids "QTc Prolonging Agents; Basic Lotions and Liniments; Cytochrome P-450 CYP3A Substrates; Cyclohexanols; Other Cold and Cough Preparations; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Antipruritics and Local Anesthetics; Calcium Channel Blockers; Cyclohexanes; Potential QTc-Prolonging Agents; Herbs and Natural Products; Vasodilating Agents; Antipruritics; Cytochrome P-450 CYP3A4 Substrates; EENT Drugs, Miscellaneous; Antiarrhythmic agents; Bradycardia-Causing Agents; Other Analgesics" CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O 15195 46506513 D00064 PA164776605 DAP000876 Menthol CHEMBL470670 236388 DB00836 Loperamide BE0000356 CACNA1A O00555 CAC1A_HUMAN blocker 17139284; 17016423; 8183255 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Church J, Fletcher EJ, Abdel-Hamid K, MacDonald JF: Loperamide blocks high-voltage-activated calcium channels and N-methyl-D-aspartate-evoked responses in rat and mouse cultured hippocampal pyramidal neurons. Mol Pharmacol. 1994 Apr;45(4):747-57." Approved Diphenylmethanes Organic compounds; Benzenoids; Benzene and substituted derivatives; Diphenylmethanes "QTc Prolonging Agents; Cytochrome P-450 CYP3A Substrates; Antipropulsives; Gastrointestinal Agents; Cytochrome P-450 CYP2C8 Substrates; Cytochrome P-450 CYP2B6 Substrates; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Antidiarrheals; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP3A Inhibitors; P-glycoprotein substrates; Cytochrome P-450 CYP3A4 Inhibitors; Alimentary Tract and Metabolism; Cytochrome P-450 CYP2D6 Substrates; Antidiarrheals, Intestinal Antiinflammatory/antiinfective Agents; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Opioid Agonist; Cytochrome P-450 CYP3A4 Substrates; Antiarrhythmic agents; Piperidines; Cytochrome P-450 CYP3A4 Inhibitors (strong); Bradycardia-Causing Agents; Moderate Risk QTc-Prolonging Agents" CN(C)C(=O)C(CCN1CCC(O)(CC1)C1=CC=C(Cl)C=C1)(C1=CC=CC=C1)C1=CC=CC=C1 2251 46504591 D08144 PA450262 DAP000425 Loperamide CHEMBL841 6468 DB00864 Tacrolimus BE0000695 FKBP1A P62942 FKB1A_HUMAN inhibitor 16289353; 17524933 "Labrande C, Velly L, Canolle B, Guillet B, Masmejean F, Nieoullon A, Pisano P: Neuroprotective effects of tacrolimus (FK506) in a model of ischemic cortical cell cultures: role of glutamate uptake and FK506 binding protein 12 kDa. Neuroscience. 2006;137(1):231-9. Epub 2005 Nov 10.@@Masri M, Rizk S, Barbari A, Stephan A, Kamel G, Rost M: An assay for the determination of sirolimus levels in the lymphocyte of transplant patients. Transplant Proc. 2007 May;39(4):1204-6." Approved; Investigational Macrolide lactams Organic compounds; Phenylpropanoids and polyketides; Macrolide lactams "Calcineurin Inhibitor Immunosuppressant; OATP1B1/SLCO1B1 Inhibitors; Myelosuppressive Agents; QTc Prolonging Agents; Enzyme Inhibitors; Cytochrome P-450 CYP3A Substrates; Hyperglycemia-Associated Agents; Nephrotoxic agents; P-glycoprotein inducers; Dermatologicals; Cytochrome P-450 CYP3A4 Inhibitors (weak); Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Immunologic Factors; Photosensitizing Agents; Cytochrome P-450 CYP3A Inhibitors; Misc. Skin and Mucous Membrane Agents; P-glycoprotein substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A4 Inhibitors; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Agents Causing Muscle Toxicity; Cytochrome P-450 CYP3A5 Substrates; Drugs causing inadvertant photosensitivity; Lactones; Polyketides; P-glycoprotein substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A4 Substrates; Immunosuppressive Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Agents for Dermatitis, Excluding Corticosteroids; Calcineurin Inhibitors; Narrow Therapeutic Index Drugs" CO[C@@H]1C[C@@H](CC[C@H]1O)\C=C(/C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@]2(O)O[C@@H]([C@H](C[C@H]2C)OC)[C@H](C[C@@H](C)C\C(C)=C\[C@@H](CC=C)C(=O)C[C@H](O)[C@H]1C)OC 167 46506004 D00107 PA451578 DAP000162 Tacrolimus CHEMBL269732 235991 DB00996 Gabapentin BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 17067834; 18299583; 23435945 "Maneuf YP, Luo ZD, Lee K: alpha2delta and the mechanism of action of gabapentin in the treatment of pain. Semin Cell Dev Biol. 2006 Oct;17(5):565-70. Epub 2006 Sep 24.@@Hendrich J, Van Minh AT, Heblich F, Nieto-Rostro M, Watschinger K, Striessnig J, Wratten J, Davies A, Dolphin AC: Pharmacological disruption of calcium channel trafficking by the alpha2delta ligand gabapentin. Proc Natl Acad Sci U S A. 2008 Mar 4;105(9):3628-33. doi: 10.1073/pnas.0708930105. Epub 2008 Feb 25.@@Kukkar A, Bali A, Singh N, Jaggi AS: Implications and mechanism of action of gabapentin in neuropathic pain. Arch Pharm Res. 2013 Mar;36(3):237-51. doi: 10.1007/s12272-013-0057-y. Epub 2013 Feb 24." Approved; Investigational Gamma amino acids and derivatives "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" "Sensory System Agents; Amines; Amino Acids, Peptides, and Proteins; Butyrates; Miscellaneous Anticonvulsants; Cycloparaffins; Central Nervous System Depressants; Photosensitizing Agents; Cyclohexanes; Amino Acids; Acids, Carbocyclic; Drugs causing inadvertant photosensitivity; Decreased Central Nervous System Disorganized Electrical Activity; Acids, Acyclic; Peripheral Nervous System Agents; Analgesics; Gabapentin and Prodrugs; Aminobutyrates; Psychotropic Drugs; Central Nervous System Agents; Tranquilizing Agents; Neurotransmitter Agents; Nervous System; Anti-epileptic Agent; Cyclohexanecarboxylic Acids; Anticonvulsants; Gabapentinoids" NCC1(CC(O)=O)CCCCC1 470 46506529 D00332 PA449720 DNC000670 Gabapentin CHEMBL940 25480 DB01023 Felodipine BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 11752352; 10525060; 17475903 "Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Furukawa T, Yamakawa T, Midera T, Sagawa T, Mori Y, Nukada T: Selectivities of dihydropyridine derivatives in blocking Ca(2+) channel subtypes expressed in Xenopus oocytes. J Pharmacol Exp Ther. 1999 Nov;291(2):464-73.@@Zahradnikova A, Minarovic I, Zahradnik I: Competitive and cooperative effects of Bay K8644 on the L-type calcium channel current inhibition by calcium channel antagonists. J Pharmacol Exp Ther. 2007 Aug;322(2):638-45. Epub 2007 May 2." Approved; Investigational Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines Cytochrome P-450 CYP2D6 Inhibitors; QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Cytochrome P-450 CYP2C8 Inhibitors; Antihypertensive Agents Indicated for Hypertension; Cardiovascular Agents; ACE Inhibitors and Calcium Channel Blockers; Beta blocking agents and calcium channel blockers; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Calcium Channel Blockers; Cytochrome P-450 CYP2C9 Inhibitors; Membrane Transport Modulators; Calcium Channel Blockers (Dihydropyridine); P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Cytochrome P-450 CYP3A5 Substrates; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); BSEP/ABCB11 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A7 Substrates; Cytochrome P-450 CYP2C8 Inhibitors (strong) CCOC(=O)C1=C(C)NC(C)=C(C1C1=C(Cl)C(Cl)=CC=C1)C(=O)OC Felodipine Metabolism Pathway; Felodipine Action Pathway drug_metabolism; drug_action 1249 46506968 D00319 PA449591 DAP000487 Felodipine CHEMBL1480 4316 DB01054 Nitrendipine BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 11752352 "Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5." Approved; Investigational Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Cardiovascular Agents; ACE Inhibitors and Calcium Channel Blockers; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Calcium Channel Blockers; Membrane Transport Modulators; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Cytochrome P-450 CYP3A5 Substrates; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; BSEP/ABCB11 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A7 Substrates CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC Nitrendipine Action Pathway drug_action 46508817 D00629 PA146096020 DAP001263 Nitrendipine CHEMBL475534 7441 DB01054 Nitrendipine BE0008715 CACNA1C O00555 CAC1A_HUMAN inhibitor 11119684; 32766273 "Mize RR, Lo F: Nitric oxide, impulse activity, and neurotrophins in visual system development(1). Brain Res. 2000 Dec 15;886(1-2):15-32. doi: 10.1016/s0006-8993(00)02750-5.@@Goswami C, Dezaki K, Wang L, Inui A, Seino Y, Yada T: Ninjin'yoeito Targets Distinct Ca(2+) Channels to Activate Ghrelin-Responsive vs. Unresponsive NPY Neurons in the Arcuate Nucleus. Front Nutr. 2020 Jul 17;7:104. doi: 10.3389/fnut.2020.00104. eCollection 2020." Approved; Investigational Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Cardiovascular Agents; ACE Inhibitors and Calcium Channel Blockers; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Calcium Channel Blockers; Membrane Transport Modulators; P-glycoprotein inhibitors; Potential QTc-Prolonging Agents; Cytochrome P-450 CYP3A5 Substrates; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; BSEP/ABCB11 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A7 Substrates CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC Nitrendipine Action Pathway drug_action 46508817 D00629 PA146096020 DAP001263 Nitrendipine CHEMBL475534 7441 DB01109 Heparin BE0000748 FGFR2 P21802 FGFR2_HUMAN 16219767 "Robinson CJ, Harmer NJ, Goodger SJ, Blundell TL, Gallagher JT: Cooperative dimerization of fibroblast growth factor 1 (FGF1) upon a single heparin saccharide may drive the formation of 2:2:1 FGF1.FGFR2c.heparin ternary complexes. J Biol Chem. 2005 Dec 23;280(51):42274-82. Epub 2005 Oct 11." Approved; Investigational Carbohydrates; Heparins or Heparinoids for Topical Use; Anticoagulants; Cardiovascular Agents; Miscellaneous Therapeutic Agents; Agents causing hyperkalemia; Thyroxine-binding globulin substrates; Blood and Blood Forming Organs; Heparin and similars; Glycosaminoglycans; Heparin Group; Ophthalmologicals; Polysaccharides; Hematologic Agents; Antivaricose Therapy; Narrow Therapeutic Index Drugs; Fibrin Modulating Agents; Sensory Organs; Vasoprotectives Fc Epsilon Receptor I Signaling in Mast Cells; Heparin Action Pathway signaling; drug_action 9045 46507594 PA449855 DAP000189 Heparin CHEMBL1909300 5224 DB01244 Bepridil BE0000356 CACNA1A O00555 CAC1A_HUMAN inhibitor 17139284; 17016423; 7565636 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Bezprozvanny I, Tsien RW: Voltage-dependent blockade of diverse types of voltage-gated Ca2+ channels expressed in Xenopus oocytes by the Ca2+ channel antagonist mibefradil (Ro 40-5967). Mol Pharmacol. 1995 Sep;48(3):540-9." Approved; Withdrawn Phenylbenzamines Organic compounds; Benzenoids; Benzene and substituted derivatives; Phenylmethylamines Cytochrome P-450 CYP2D6 Inhibitors; QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Phenylalkylamine Derivatives; Non-Selective Calcium Channel Blockers; Hypotensive Agents; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Calcium Channel Blockers; Membrane Transport Modulators; P-glycoprotein inhibitors; Cytochrome P-450 CYP2D6 Substrates; Pyrrolidines; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Antiarrhythmic agents; Highest Risk QTc-Prolonging Agents; Bradycardia-Causing Agents CC(C)COCC(CN(CC1=CC=CC=C1)C1=CC=CC=C1)N1CCCC1 46506353 D07520 PA164754755 DAP000525 Bepridil CHEMBL1008 1436 DB01712 "(3R)-4-(p-toluenesulfonyl)-1,4-thiazane-3-carboxylicacid-L-phenylalanine ethyl ester" BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Phenylalanine and derivatives "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" CCOC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@@H]1CSCCN1S(=O)(=O)C1=CC=C(C)C=C1 46507878 DB01723 "{3-[3-(3,4-Dimethoxy-Phenyl)-1-(1-{1-[2-(3,4,5-Trimethoxy-Phenyl)-Butyryl]-Piperidin-2yl}-Vinyloxy)-Propyl]-Phenoxy}-Acetic Acid" BE0000695 FKBP1A P62942 FKB1A_HUMAN 17139284; 17016423; 10592235 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental "Linear 1,3-diarylpropanoids" "Organic compounds; Phenylpropanoids and polyketides; Linear 1,3-diarylpropanoids" [H][C@](CCC1=CC(OC)=C(OC)C=C1)(OC(=O)[C@]1([H])CCCCN1C(=O)[C@@]([H])(CC)C1=CC(OC)=C(OC)C(OC)=C1)C1=CC(OCC(O)=O)=CC=C1 46506401 CHEMBL110674 DB01890 "N,N-Bis(3-(D-gluconamido)propyl)deoxycholamide" BE0003418 IGF1 P05019 IGF1_HUMAN 10592235; 11551198 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.@@Vajdos FF, Ultsch M, Schaffer ML, Deshayes KD, Liu J, Skelton NJ, de Vos AM: Crystal structure of human insulin-like growth factor-1: detergent binding inhibits binding protein interactions. Biochemistry. 2001 Sep 18;40(37):11022-9." Experimental "Dihydroxy bile acids, alcohols and derivatives" "Organic compounds; Lipids and lipid-like molecules; Steroids and steroid derivatives; Bile acids, alcohols and derivatives" [H][C@@]1(CC[C@@]2([H])[C@]3([H])CC[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C)[C@H](C)CCC(=O)N(CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO)CCCNC(=O)[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO 46505499 DB01901 Sucrosofate BE0000748 FGFR2 P21802 FGFR2_HUMAN ligand 15047176 "Hung KW, Kumar TK, Chi YH, Chiu IM, Yu C: Molecular cloning, overexpression, and characterization of the ligand-binding D2 domain of fibroblast growth factor receptor. Biochem Biophys Res Commun. 2004 Apr 23;317(1):253-8." Experimental Disaccharide sulfates Organic compounds; Organic oxygen compounds; Organooxygen compounds; Carbohydrates and carbohydrate conjugates Anti-Ulcer Agents; Oligosaccharides; Carbohydrates; Polysaccharides; Disaccharides; Gastrointestinal Agents OS(=O)(=O)OC[C@H]1O[C@@](COS(O)(=O)=O)(O[C@H]2O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]2OS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@@H]1OS(O)(=O)=O 46504489 CHEMBL1235872 DB01951 Gpi-1046 BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental N-acyl-alpha amino acids "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" [H][C@]1(CCCN1C(=O)C(=O)C(C)(C)CC)C(=O)OCCCC1=CN=CC=C1 46506804 CHEMBL6367 DB02058 3-[4-(1-formylpiperazin-4-yl)-benzylidenyl]-2-indolinone BE0000748 FGFR2 P21802 FGFR2_HUMAN 11752352 "Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5." Experimental Phenylpiperazines Organic compounds; Organoheterocyclic compounds; Diazinanes; Piperazines Tyrosine Kinase Inhibitors [H]N1C(=O)C(CC2=CC=C(C=C2)N2CCN(CC2)C=O)C2=CC=CC=C12 46508294 DNC001385 DB02311 Methyl Methylsulfinylmethyl Sulfide BE0000695 FKBP1A P62942 FKB1A_HUMAN 17139284; 17016423; 10592235 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Sulfoxides Organic compounds; Organosulfur compounds; Sulfoxides CSC[S@](C)=O 46507571 DB02491 4-[4-(1-Amino-1-Methylethyl)Phenyl]-5-Chloro-N-[4-(2-Morpholin-4-Ylethyl)Phenyl]Pyrimidin-2-Amine BE0000748 FGFR2 P21802 FGFR2_HUMAN 17139284; 17016423 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34." Experimental Phenylpyrimidines Organic compounds; Organoheterocyclic compounds; Diazines; Pyrimidines and pyrimidine derivatives CC(C)(N)C1=CC=C(C=C1)C1=NC(NC2=CC=C(CCN3CCOCC3)C=C2)=NC=C1Cl 46505042 CHEMBL233209 DB02643 "N-Dodecyl-N,N-Dimethyl-3-Ammonio-1-Propanesulfonate" BE0003418 IGF1 P05019 IGF1_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Organosulfonic acids Organic compounds; Organic acids and derivatives; Organic sulfonic acids and derivatives; Organosulfonic acids and derivatives "Nitrogen Compounds; Detergents; Amines; Onium Compounds; Ammonium Compounds; Surface-Active Agents; Household Products; Compounds used in a research, industrial, or household setting" CCCCCCCCCCCC[N+](C)(C)CCCS(O)(=O)=O 46505495 DB02888 FKB-001 BE0000695 FKBP1A P62942 FKB1A_HUMAN 17139284; 17016423; 10592235 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Alpha amino acid esters "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" COC1=CC(=CC(OC)=C1OC)C(F)(F)C(=O)N1CCCC[C@H]1C(=O)O[C@@H](CCCC1=CC=CC=C1)CCCC1=CN=CC=C1 46508860 DB03338 Heptyl glucoside BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Fatty acyl glycosides of mono- and disaccharides Organic compounds; Lipids and lipid-like molecules; Fatty Acyls; Fatty acyl glycosides CCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O 46506841 2462498 DB03621 "L-709,587" BE0000695 FKBP1A P62942 FKB1A_HUMAN 17139284; 17016423; 10592235 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Macrolide lactams Organic compounds; Phenylpropanoids and polyketides; Macrolide lactams [H]\C(=C(\C)[C@@]1([H])OC(=O)[C@]2([H])CCCCN2C(=O)C(=O)[C@]2(O)O[C@@]([H])([C@]([H])(C[C@@]2([H])C)OC)[C@]([H])(C[C@@]([H])(C)[C@]([H])(O)\C(C)=C([H])\[C@@]([H])(CC)C(=O)C[C@]([H])(O)[C@@]1([H])C)OC)[C@]1([H])CC[C@@]([H])(OC2=CC=C3N(C)C=CC3=C2)[C@@]([H])(C1)OC 46504459 DB04012 "(3r)-4-(P-Toluenesulfonyl)-1,4-Thiazane-3-Carboxylicacid-L-Leucine" BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Dipeptides "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" [H][C@@](CC(C)C)(NC(=O)[C@]1([H])CSCCN1S(=O)(=O)C1=CC=C(C)C=C1)C(O)=O 46506052 DB04094 4-hydroxybutan-2-one BE0000695 FKBP1A P62942 FKB1A_HUMAN 17139284; 17016423; 10592235 "Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.@@Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.@@Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Beta-hydroxy ketones Organic compounds; Organic oxygen compounds; Organooxygen compounds; Carbonyl compounds Ketones CC(=O)CCO 46508666 DB04838 Cyclandelate BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 10659603 Pascual J: [New prospects in the treatment of migraine]. Neurologia. 1999 Dec;14 Suppl 6:26-35. Approved Benzene and substituted derivatives Organic compounds; Benzenoids; Benzene and substituted derivatives "Antiarrhythmic agents; Peripheral Vasodilators; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Acids, Carbocyclic; Hydroxy Acids; Calcium Channel Blockers; Vasodilating Agents; Cytochrome P-450 CYP3A Substrates; Bradycardia-Causing Agents; Cytochrome P-450 CYP3A4 Substrates; Mandelic Acids" CC1CC(CC(C)(C)C1)OC(=O)C(O)C1=CC=CC=C1 5200 46505740 PA164748026 Cyclandelate CHEMBL1480987 2970 DB05814 GPI-1485 BE0000695 FKBP1A P62942 FKB1A_HUMAN Investigational Proline and derivatives "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Lactones; Cytochrome P-450 CYP3A4 Inhibitors CCC(C)(C)C(=O)C(=O)N1CCC[C@H]1C(O)=O 347827745 DB06283 Ziconotide BE0000356 CACNA1A O00555 CAC1A_HUMAN inhibitor 26344359 "Wang F, Yan Z, Liu Z, Wang S, Wu Q, Yu S, Ding J, Dai Q: Molecular basis of toxicity of N-type calcium channel inhibitor MVIIA. Neuropharmacology. 2016 Feb;101:137-45. doi: 10.1016/j.neuropharm.2015.08.047. Epub 2015 Sep 4." Approved "Sensory System Agents; Protective Agents; N-Calcium Channel Receptor Antagonists; Marine Toxins; Central Nervous System Depressants; Fluids and Secretions; Calcium Channel Blockers; Toxins, Biological; Membrane Transport Modulators; Complex Mixtures; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Analgesics, Non-Narcotic; Mollusk Venoms; Peripheral Nervous System Agents; Analgesics; Compounds used in a research, industrial, or household setting; Antiarrhythmic agents; Central Nervous System Agents; Nervous System; Venoms; Narrow Therapeutic Index Drugs; Conotoxins; Neuroprotective Agents; Calcium Channels, N-Type" [H][C@]12CSSC[C@]3([H])NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CSSC[C@]([H])(NC(=O)[C@]([H])(CSSC[C@H](NC(=O)[C@H](CCCCN)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC1=O)C(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC1=CC=C(O)C=C1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC3=O)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N2 347910345 D06363 Ziconotide CHEMBL4594214 68503 DB06446 Dotarizine BE0000356 CACNA1A O00555 CAC1A_HUMAN 14637173 "Ruiz-Nuno A, Mayorgas I, Hernandez-Guijo JM, Olivares R, Garcia AG, Gandia L: Antimigraine dotarizine blocks P/Q Ca2+ channels and exocytosis in a voltage-dependent manner in chromaffin cells. Eur J Pharmacol. 2003 Nov 14;481(1):41-50." Investigational Diphenylmethanes Organic compounds; Benzenoids; Benzene and substituted derivatives; Diphenylmethanes Antiarrhythmic agents; Cardiovascular Agents; Serotonin Agents; Central Nervous System Depressants; Agents causing hyperkalemia; Cytochrome P-450 Substrates; Vasodilating Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP3A Substrates; Neurotransmitter Agents; Bradycardia-Causing Agents; Serotonin Receptor Antagonists; Benzene Derivatives; Cytochrome P-450 CYP3A4 Substrates; Membrane Transport Modulators; Antidepressive Agents C(CN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1)CC1(OCCO1)C1=CC=CC=C1 Dotarizine CHEMBL2106316 DB06712 Nilvadipine BE0000691 CACNA2D1 P54289 CA2D1_HUMAN inhibitor 16484345; 11752352; 20933604 "Li GR, Deng XL, Sun H, Chung SS, Tse HF, Lau CP: Ion channels in mesenchymal stem cells from rat bone marrow. Stem Cells. 2006 Jun;24(6):1519-28. Epub 2006 Feb 16.@@Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5.@@Araie M, Mayama C: Use of calcium channel blockers for glaucoma. Prog Retin Eye Res. 2011 Jan;30(1):54-71. doi: 10.1016/j.preteyeres.2010.09.002. Epub 2010 Oct 8." Approved; Investigational Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Cytochrome P-450 CYP2A6 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inhibitors; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP3A4 Inhibitors; Membrane Transport Modulators; Cytochrome P-450 CYP2E1 Substrates; Cytochrome P-450 CYP2A6 Inhibitors; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; Antiarrhythmic agents; Cytochrome P-450 CYP2C19 Inhibitors; Bradycardia-Causing Agents; Moderate Risk QTc-Prolonging Agents COC(=O)C1=C(NC(C)=C(C1C1=CC(=CC=C1)[N+]([O-])=O)C(=O)OC(C)C)C#N 99443264 D01908 PA165958385 Nilvadipine CHEMBL517427 53692 DB06751 Drotaverine BE0008715 CACNA1C O00555 CAC1A_HUMAN inhibitor 12163106; 12823389; 27738091 "Tomoskozi Z, Finance O, Aranyi P: Drotaverine interacts with the L-type Ca(2+) channel in pregnant rat uterine membranes. Eur J Pharmacol. 2002 Aug 2;449(1-2):55-60.@@Romics I, Molnar DL, Timberg G, Mrklic B, Jelakovic B, Koszegi G, Blasko G: The effect of drotaverine hydrochloride in acute colicky pain caused by renal and ureteric stones. BJU Int. 2003 Jul;92(1):92-6.@@Patai Z, Guttman A, Mikus EG: Potential L-Type Voltage-Operated Calcium Channel Blocking Effect of Drotaverine on Functional Models. J Pharmacol Exp Ther. 2016 Dec;359(3):442-451. doi: 10.1124/jpet.116.237271. Epub 2016 Oct 13." Approved; Investigational Tetrahydroisoquinolines Organic compounds; Organoheterocyclic compounds; Tetrahydroisoquinolines "Sensory System Agents; Autonomic Agents; Cardiovascular Agents; Alkaloids; Alimentary Tract and Metabolism; Heterocyclic Compounds, Fused-Ring; Vasodilating Agents; Papaverine and Derivatives; Isoquinolines; Peripheral Nervous System Agents; Analgesics; Parasympatholytics; Phosphodiesterase Inhibitors; Benzylisoquinolines; Phosphodiesterase 4 Inhibitors; Central Nervous System Agents; Drugs for Functional Gastrointestinal Disorders; Opiate Alkaloids" CCOC1=C(OCC)C=C(\C=C2/NCCC3=CC(OCC)=C(OCC)C=C23)C=C1 99443287 PA165958398 Drotaverine CHEMBL551978 23684 DB08231 Myristic acid BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Long-chain fatty acids Organic compounds; Lipids and lipid-like molecules; Fatty Acyls; Fatty acids and conjugates Myristic Acids; Fatty Acids; Lipids CCCCCCCCCCCCCC(O)=O Fatty Acid Biosynthesis metabolic 99444702 Myristic_acid CHEMBL111077 1356758 DB08520 "(21S)-1AZA-4,4-DIMETHYL-6,19-DIOXA-2,3,7,20-TETRAOXOBICYCLO[19.4.0] PENTACOSANE" BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental Macrolide lactams Organic compounds; Phenylpropanoids and polyketides; Macrolide lactams [H][C@@]12CCCCN1C(=O)C(=O)C(C)(C)COC(=O)CCCCCCCCCCCOC2=O 99444991 CHEMBL1235837 DB08597 Dorsomorphin BE0000695 FKBP1A P62942 FKB1A_HUMAN 10592235 "Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42." Experimental "Pyrazolo[1,5-a]pyrimidines" "Organic compounds; Organoheterocyclic compounds; Pyrazolopyrimidines; Pyrazolo[1,5-a]pyrimidines" "Enzyme Inhibitors; Protein Kinase Inhibitors; AMP-Activated Protein Kinases, antagonists & inhibitors" C(CN1CCCCC1)OC1=CC=C(C=C1)C1=CN2N=CC(=C2N=C1)C1=CC=NC=C1 99445068 CHEMBL478629 DB08872 Gabapentin enacarbil BE0000691 CACNA2D1 P54289 CA2D1_HUMAN Approved; Investigational Gamma amino acids and derivatives "Organic compounds; Organic acids and derivatives; Carboxylic acids and derivatives; Amino acids, peptides, and analogues" "Amino Acids; Aminobutyrates; Central Nervous System Depressants; Acids, Acyclic; Anti-epileptic Agent; Drugs that are Mainly Renally Excreted; Amino Acids, Peptides, and Proteins; Butyrates; Gabapentin and Prodrugs" CC(C)C(=O)OC(C)OC(=O)NCC1(CC(O)=O)CCCCC1 347827805 D09539 Gabapentin_enacarbil CHEMBL1628502 1101333 DB08896 Regorafenib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor Approved Diarylethers Organic compounds; Organic oxygen compounds; Organooxygen compounds; Ethers Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP3A Substrates; Amides; Benzene Derivatives; UGT1A1 Inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; UGT1A9 Inhibitors; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; UGT1A9 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Antineoplastic Agents; Kinase Inhibitor; P-glycoprotein inhibitors; Hepatotoxic Agents; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Tyrosine Kinase Inhibitors; P-glycoprotein substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A4 Substrates; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; UGT1A9 Substrates; Cytochrome P-450 CYP2C19 Inhibitors; Bradycardia-Causing Agents; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Narrow Therapeutic Index Drugs CNC(=O)C1=CC(OC2=CC(F)=C(NC(=O)NC3=CC=C(Cl)C(=C3)C(F)(F)F)C=C2)=CC=N1 22042 175427139 D10138 Regorafenib CHEMBL1946170 1312397 DB08901 Ponatinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 23468082 "Gozgit JM, Squillace RM, Wongchenko MJ, Miller D, Wardwell S, Mohemmad Q, Narasimhan NI, Wang F, Clackson T, Rivera VM: Combined targeting of FGFR2 and mTOR by ponatinib and ridaforolimus results in synergistic antitumor activity in FGFR2 mutant endometrial cancer models. Cancer Chemother Pharmacol. 2013 May;71(5):1315-23. doi: 10.1007/s00280-013-2131-z. Epub 2013 Mar 7." Approved; Investigational Benzanilides Organic compounds; Benzenoids; Benzene and substituted derivatives; Anilides Myelosuppressive Agents; Cytochrome P-450 CYP2C8 Substrates with a Narrow Therapeutic Index; Enzyme Inhibitors; Cytochrome P-450 CYP3A Substrates; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Substrates; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Bcr-Abl Tyrosine Kinase Inhibitors; Cytochrome P-450 CYP2D6 Substrates with a Narrow Therapeutic Index; P-glycoprotein substrates; Cytochrome P-450 CYP3A5 Substrates with a Narrow Therapeutic Index; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; Cytochrome P-450 CYP3A5 Substrates; P-glycoprotein inhibitors; Cytochrome P-450 CYP2D6 Substrates; Hepatotoxic Agents; Tyrosine Kinase Inhibitors; P-glycoprotein substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP3A4 Substrates; Immunosuppressive Agents; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Narrow Therapeutic Index Drugs CN1CCN(CC2=CC=C(NC(=O)C3=CC(C#CC4=CN=C5C=CC=NN45)=C(C)C=C3)C=C2C(F)(F)F)CC1 Ponatinib Inhibition of BCR-ABL drug_action 22576 175427142 D09950 PA165980594 Ponatinib CHEMBL1171837 1364347 DB09078 Lenvatinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 17943726 "Matsui J, Yamamoto Y, Funahashi Y, Tsuruoka A, Watanabe T, Wakabayashi T, Uenaka T, Asada M: E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition. Int J Cancer. 2008 Feb 1;122(3):664-71." Approved; Investigational Quinoline carboxamides Organic compounds; Organoheterocyclic compounds; Quinolines and derivatives; Quinoline carboxamides "Cytochrome P-450 CYP2C8 Inhibitors (moderate); Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; OATP1B1/SLCO1B1 Inhibitors; Receptor Tyrosine Kinase Inhibitors; OCT2 Inhibitors; QTc Prolonging Agents; Enzyme Inhibitors; Cytochrome P-450 CYP3A Substrates; Amides; Benzene Derivatives; Cytochrome P-450 CYP3A4 Inhibitors (weak); OAT1/SLC22A6 inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP2C19 inhibitors (strength unknown); P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; P-glycoprotein inhibitors; OATP1B3 inhibitors; Heterocyclic Compounds, Fused-Ring; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Tyrosine Kinase Inhibitors; Cytochrome P-450 CYP3A4 Inducers (weak); Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP2D6 Inhibitors (strength unknown); Antineoplastic and Immunomodulating Agents; OAT3/SLC22A8 Inhibitors; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2B6 Inhibitors (strength unknown); Moderate Risk QTc-Prolonging Agents; Cytochrome P-450 CYP1A2 Inhibitors (strength unknown)" COC1=C(C=C2C(OC3=CC=C(NC(=O)NC4CC4)C(Cl)=C3)=CC=NC2=C1)C(N)=O 22675 310265006 D09919 PA166153472 Lenvatinib CHEMBL1289601 1603296 DB09079 Nintedanib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 18559524; 31016670 "Hilberg F, Roth GJ, Krssak M, Kautschitsch S, Sommergruber W, Tontsch-Grunt U, Garin-Chesa P, Bader G, Zoephel A, Quant J, Heckel A, Rettig WJ: BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res. 2008 Jun 15;68(12):4774-82. doi: 10.1158/0008-5472.CAN-07-6307.@@Wind S, Schmid U, Freiwald M, Marzin K, Lotz R, Ebner T, Stopfer P, Dallinger C: Clinical Pharmacokinetics and Pharmacodynamics of Nintedanib. Clin Pharmacokinet. 2019 Sep;58(9):1131-1147. doi: 10.1007/s40262-019-00766-0." Approved Indolecarboxylic acids Organic compounds; Organoheterocyclic compounds; Indoles and derivatives; Indolecarboxylic acids and derivatives "Kinase Inhibitor; OCT1 substrates; P-glycoprotein inhibitors; Antineoplastic and Immunomodulating Agents; Heterocyclic Compounds, Fused-Ring; Cytochrome P-450 Substrates; Cytochrome P-450 CYP3A4 Substrates; Enzyme Inhibitors; UGT1A1 Substrates; OCT1 inhibitors; Cytochrome P-450 CYP3A Substrates; Tyrosine Kinase Inhibitors; Antifibrotic Agents; P-glycoprotein substrates; Cytochrome P-450 CYP3A4 Substrates (strength unknown); Antineoplastic Agents; Protein Kinase Inhibitors" COC(=O)C1=CC=C2C(NC(=O)\C2=C(/NC2=CC=C(C=C2)N(C)C(=O)CN2CCN(C)CC2)C2=CC=CC=C2)=C1 22614 310265007 D10481 Nintedanib CHEMBL502835 1592737 DB09089 Trimebutine BE0008715 CACNA1C O00555 CAC1A_HUMAN inhibitor 8220900; 26424038 "Nagasaki M, Komori S, Ohashi H: Effect of trimebutine on voltage-activated calcium current in rabbit ileal smooth muscle cells. Br J Pharmacol. 1993 Sep;110(1):399-403.@@Radulovic M, Anand P, Korsten MA, Gong B: Targeting Ion Channels: An Important Therapeutic Implication in Gastrointestinal Dysmotility in Patients With Spinal Cord Injury. J Neurogastroenterol Motil. 2015 Oct 1;21(4):494-502. doi: 10.5056/jnm15061." Approved Gallic acid and derivatives Organic compounds; Benzenoids; Benzene and substituted derivatives; Benzoic acids and derivatives "Hydroxybenzoate Ethers; QTc Prolonging Agents; Cytochrome P-450 CYP3A Substrates; Hydroxybenzoates; Agents producing tachycardia; Benzene Derivatives; Autonomic Agents; Gastrointestinal Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Benzoates; Hydroxy Acids; Calcium Channel Blockers; Phenols; Synthetic Anticholinergics, Esters With Tertiary Amino Group; Drugs that are Mainly Renally Excreted; Alimentary Tract and Metabolism; Potential QTc-Prolonging Agents; Anticholinergic Agents; Acids, Carbocyclic; Prokinetic Agents; Cytochrome P-450 CYP3A4 Substrates; Peripheral Nervous System Agents; Antimuscarinics Antispasmodics; Parasympatholytics; Phenyl Ethers; Antiarrhythmic agents; Muscarinic Antagonists; Drugs for Functional Gastrointestinal Disorders; Bradycardia-Causing Agents" CCC(COC(=O)C1=CC(OC)=C(OC)C(OC)=C1)(N(C)C)C1=CC=CC=C1 1925 310265016 Trimebutine CHEMBL190044 10819 DB09130 Copper BE0008964 HNRNPL P14866 HNRPL_HUMAN 15359738 "Smith SD, She YM, Roberts EA, Sarkar B: Using immobilized metal affinity chromatography, two-dimensional electrophoresis and mass spectrometry to identify hepatocellular proteins with copper-binding ability. J Proteome Res. 2004 Jul-Aug;3(4):834-40." Approved; Investigational Homogeneous transition metal compounds Inorganic compounds; Homogeneous metal compounds; Homogeneous transition metal compounds "Minerals; Decreased Sperm Motility; Physiological Phenomena; Inhibit Ovum Fertilization; Metals; Replacement Preparations; Diet, Food, and Nutrition; Transition Elements; Elements; Food; Decreased Embryonic Implantation; Copper-containing Intrauterine Device; Trace Elements; Metals, Heavy; Micronutrients" [Cu] 582 310265045 PA449114 Copper 2837 DB09231 Benidipine BE0008715 CACNA1C O00555 CAC1A_HUMAN antagonist 16565579 "Yao K, Nagashima K, Miki H: Pharmacological, pharmacokinetic, and clinical properties of benidipine hydrochloride, a novel, long-acting calcium channel blocker. J Pharmacol Sci. 2006 Apr;100(4):243-61. Epub 2006 Mar 25." Experimental N-benzylpiperidines Organic compounds; Organoheterocyclic compounds; Piperidines; Benzylpiperidines QTc Prolonging Agents; Cytochrome P-450 CYP3A4 Inhibitors (moderate); Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Membrane Transport Modulators; Cytochrome P-450 CYP3A4 Inhibitors; Cytochrome P-450 CYP3A5 Substrates; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Dihydropyridines; Cytochrome P-450 CYP3A4 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents; Moderate Risk QTc-Prolonging Agents COC(=O)C1=C(C)NC(C)=C([C@@H]1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)O[C@@H]1CCCN(CC2=CC=CC=C2)C1 310265135 Benidipine CHEMBL2105555 DB09232 Cilnidipine BE0008715 CACNA1C O00555 CAC1A_HUMAN antagonist 25336921 "Lee J, Lee H, Jang K, Lim KS, Shin D, Yu KS: Evaluation of the pharmacokinetic and pharmacodynamic drug interactions between cilnidipine and valsartan, in healthy volunteers. Drug Des Devel Ther. 2014 Oct 8;8:1781-8. doi: 10.2147/DDDT.S68574. eCollection 2014." Investigational Dihydropyridinecarboxylic acids and derivatives Organic compounds; Organoheterocyclic compounds; Pyridines and derivatives; Hydropyridines Antiarrhythmic agents; Hypotensive Agents; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Vasodilating Agents; Calcium Channel Blockers; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Bradycardia-Causing Agents; Membrane Transport Modulators; Cytochrome P-450 CYP3A4 Substrates; Dihydropyridine Derivatives; Pyridines COCCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC(=C1)[N+]([O-])=O)C(=O)OC\C=C\C1=CC=CC=C1 310265136 D01173 Cilnidipine CHEMBL452076 DB09236 Lacidipine BE0008715 CACNA1C O00555 CAC1A_HUMAN antagonist 9051306 "Cerbai E, Giotti A, Mugelli A: Characteristics of L-type calcium channel blockade by lacidipine in guinea-pig ventricular myocytes. Br J Pharmacol. 1997 Feb;120(4):667-75. doi: 10.1038/sj.bjp.0700951." Approved; Investigational Cinnamic acid esters Organic compounds; Phenylpropanoids and polyketides; Cinnamic acids and derivatives; Cinnamic acid esters QTc Prolonging Agents; Antihypertensive Agents; Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Dihydropyridine Derivatives; Pyridines; Hypotensive Agents; Mutagens; Cardiovascular Agents; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Calcium Channel Blockers; Membrane Transport Modulators; Potential QTc-Prolonging Agents; Vasodilating Agents; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP3A4 Substrates; Antiarrhythmic agents; Bradycardia-Causing Agents CCOC(=O)C1=C(C)NC(C)=C(C1C1=CC=CC=C1\C=C\C(=O)OC(C)(C)C)C(=O)OCC 310265140 D04657 Lacidipine CHEMBL460291 28382 DB09238 Manidipine BE0008715 CACNA1C O00555 CAC1A_HUMAN blocker 15329044 "McKeage K, Scott LJ: Manidipine: a review of its use in the management of hypertension. Drugs. 2004;64(17):1923-40." Approved; Investigational Diphenylmethanes Organic compounds; Benzenoids; Benzene and substituted derivatives; Diphenylmethanes Cytochrome P-450 CYP2B6 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors; Antihypertensive Agents; Cytochrome P-450 CYP2D6 Inhibitors (weak); Cytochrome P-450 CYP3A Substrates; Selective Calcium Channel Blockers With Mainly Vascular Effects; Benzene Derivatives; Cytochrome P-450 CYP3A4 Inhibitors (weak); Dihydropyridine Derivatives; Pyridines; Cardiovascular Agents; ACE Inhibitors and Calcium Channel Blockers; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Cytochrome P-450 Enzyme Inhibitors; Calcium Channel Blockers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP2C19 Inhibitors (weak); Cytochrome P-450 CYP3A4 Inhibitors; Membrane Transport Modulators; Nitro Compounds; Cytochrome P-450 CYP2B6 Inhibitors (weak); Vasodilating Agents; Calcium-Regulating Hormones and Agents; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Substrates; Antiarrhythmic agents; Cytochrome P-450 CYP2C19 Inhibitors; Cytochrome P-450 CYP2D6 Inhibitors (moderate); Bradycardia-Causing Agents COC(=O)C1=C(C)NC(C)=C(C1C1=CC(=CC=C1)N(=O)=O)C(=O)OCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=CC=C1 347827830 Manidipine CHEMBL1085699 29275 DB10770 Foreskin fibroblast (neonatal) BE0000748 FGFR2 P21802 FGFR2_HUMAN agonist Approved Allogeneic Cultured Cell Scaffold 1427137 DB10772 Foreskin keratinocyte (neonatal) BE0000748 FGFR2 P21802 FGFR2_HUMAN agonist Approved Allogeneic Cultured Cell Scaffold 1427138 DB11886 Infigratinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor Approved; Investigational Phenylpiperazines Organic compounds; Organoheterocyclic compounds; Diazinanes; Piperazines "OATP1B1/SLCO1B1 Inhibitors; OCT2 Inhibitors; Cytochrome P-450 CYP3A Substrates; Amides; Benzene Derivatives; Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors; MATE 1 Inhibitors; Protein Kinase Inhibitors; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; P-glycoprotein substrates; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; P-glycoprotein inhibitors; OATP1B3 inhibitors; Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors; Fibroblast Growth Factor 2, antagonists & inhibitors; MATE inhibitors; Tyrosine Kinase Inhibitors; Receptors, Fibroblast Growth Factor, antagonists & inhibitors; Cytochrome P-450 CYP3A4 Substrates; Antineoplastic and Immunomodulating Agents; MATE 2 Inhibitors; BSEP/ABCB11 Inhibitors; OCT1 inhibitors; Cytochrome P-450 CYP3A4 Substrates (strength unknown)" CCN1CCN(CC1)C1=CC=C(NC2=CC(=NC=N2)N(C)C(=O)NC2=C(Cl)C(OC)=CC(OC)=C2Cl)C=C1 23657 347828222 Infigratinib CHEMBL1852688 2550729 DB12010 Fostamatinib BE0009443 FER P16591 FER_HUMAN inhibitor 26516587 "Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4." Approved; Investigational Methoxyanilines Organic compounds; Benzenoids; Benzene and substituted derivatives; Aniline and substituted anilines Amines; Cytochrome P-450 CYP3A Substrates; UGT1A1 Inhibitors; Pyridines; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Experimental Unapproved Treatments for COVID-19; Cytochrome P-450 Enzyme Inhibitors; Oxazines; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Kinase Inhibitor; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Hemostatics; Vasodilating Agents; Tyrosine Kinase Inhibitors; Cytochrome P-450 CYP3A4 Substrates; UGT1A9 Substrates; Phosphodiesterase 5 Inhibitors COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC 23528 347828328 Fostamatinib CHEMBL2103830 2044896 DB12010 Fostamatinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 26516587 "Rolf MG, Curwen JO, Veldman-Jones M, Eberlein C, Wang J, Harmer A, Hellawell CJ, Braddock M: In vitro pharmacological profiling of R406 identifies molecular targets underlying the clinical effects of fostamatinib. Pharmacol Res Perspect. 2015 Oct;3(5):e00175. doi: 10.1002/prp2.175. Epub 2015 Sep 4." Approved; Investigational Methoxyanilines Organic compounds; Benzenoids; Benzene and substituted derivatives; Aniline and substituted anilines Amines; Cytochrome P-450 CYP3A Substrates; UGT1A1 Inhibitors; Pyridines; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Experimental Unapproved Treatments for COVID-19; Cytochrome P-450 Enzyme Inhibitors; Oxazines; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Kinase Inhibitor; Blood and Blood Forming Organs; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Hemostatics; Vasodilating Agents; Tyrosine Kinase Inhibitors; Cytochrome P-450 CYP3A4 Substrates; UGT1A9 Substrates; Phosphodiesterase 5 Inhibitors COC1=CC(NC2=NC=C(F)C(NC3=NC4=C(OC(C)(C)C(=O)N4COP(O)(O)=O)C=C3)=N2)=CC(OC)=C1OC 23528 347828328 Fostamatinib CHEMBL2103830 2044896 DB12147 Erdafitinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 28965185; 26324363 "Nishina T, Takahashi S, Iwasawa R, Noguchi H, Aoki M, Doi T: Safety, pharmacokinetic, and pharmacodynamics of erdafitinib, a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor, in patients with advanced or refractory solid tumors. Invest New Drugs. 2018 Jun;36(3):424-434. doi: 10.1007/s10637-017-0514-4. Epub 2017 Sep 30.@@Tabernero J, Bahleda R, Dienstmann R, Infante JR, Mita A, Italiano A, Calvo E, Moreno V, Adamo B, Gazzah A, Zhong B, Platero SJ, Smit JW, Stuyckens K, Chatterjee-Kishore M, Rodon J, Peddareddigari V, Luo FR, Soria JC: Phase I Dose-Escalation Study of JNJ-42756493, an Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients With Advanced Solid Tumors. J Clin Oncol. 2015 Oct 20;33(30):3401-8. doi: 10.1200/JCO.2014.60.7341. Epub 2015 Aug 31." Approved; Investigational Alkyldiarylamines Organic compounds; Organic nitrogen compounds; Organonitrogen compounds; Amines "OCT2 Inhibitors; Cytochrome P-450 CYP3A Substrates; Protein Kinase Inhibitors; Cytochrome P-450 Enzyme Inducers; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP3A4 Inducers; Cytochrome P-450 CYP2C9 Substrates with a Narrow Therapeutic Index; P-glycoprotein substrates; Cytochrome P-450 CYP3A4 Inhibitors; Antineoplastic Agents; Tumor Suppressor Proteins; Kinase Inhibitor; P-glycoprotein inhibitors; Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors; Heterocyclic Compounds, Fused-Ring; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Tyrosine Kinase Inhibitors; P-glycoprotein substrates with a Narrow Therapeutic Index; Receptors, Fibroblast Growth Factor, antagonists & inhibitors; Cytochrome P-450 CYP3A4 Substrates; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 CYP3A Inducers; Narrow Therapeutic Index Drugs" COC1=CC(=CC(OC)=C1)N(CCNC(C)C)C1=CC=C2N=CC(=NC2=C1)C1=CN(C)N=C1 23382 347828443 Erdafitinib CHEMBL3545376 2123125 DB13746 Bioallethrin BE0008717 CACNA1A O00555 CAC1A_HUMAN blocker 14634047 "Hildebrand ME, McRory JE, Snutch TP, Stea A: Mammalian voltage-gated calcium channels are potently blocked by the pyrethroid insecticide allethrin. J Pharmacol Exp Ther. 2004 Mar;308(3):805-13. doi: 10.1124/jpet.103.058792. Epub 2003 Nov 21." Approved; Experimental "Cytochrome P-450 CYP3A Substrates; Pesticides; Pyrethrins; Insecticides; Cytochrome P-450 CYP2C8 Substrates; Stereoisomerism; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Antiparasitic Products, Insecticides and Repellents; Calcium Channel Blockers; Pyrethrines, Incl. Synthetic Compounds; Monoterpenes; Cytochrome P-450 CYP2C19 Substrates; Terpenes; Ectoparasiticides, Incl. Scabicides; Cytochrome P-450 CYP3A4 Substrates; Compounds used in a research, industrial, or household setting; Antiarrhythmic agents; Cyclopentane Monoterpenes; Cytochrome P-450 CYP2C9 Substrates; Agrochemicals; Bradycardia-Causing Agents; Toxic Actions; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents" CC(C)=CC1C(C(=O)OC2CC(=O)C(CC=C)=C2C)C1(C)C 2024 347829312 Bioallethrin CHEMBL1872535 19338 DB13746 Bioallethrin BE0008715 CACNA1C O00555 CAC1A_HUMAN blocker 14634047 "Hildebrand ME, McRory JE, Snutch TP, Stea A: Mammalian voltage-gated calcium channels are potently blocked by the pyrethroid insecticide allethrin. J Pharmacol Exp Ther. 2004 Mar;308(3):805-13. doi: 10.1124/jpet.103.058792. Epub 2003 Nov 21." Approved; Experimental "Cytochrome P-450 CYP3A Substrates; Pesticides; Pyrethrins; Insecticides; Cytochrome P-450 CYP2C8 Substrates; Stereoisomerism; Cytochrome P-450 Substrates; Agents causing hyperkalemia; Antiparasitic Products, Insecticides and Repellents; Calcium Channel Blockers; Pyrethrines, Incl. Synthetic Compounds; Monoterpenes; Cytochrome P-450 CYP2C19 Substrates; Terpenes; Ectoparasiticides, Incl. Scabicides; Cytochrome P-450 CYP3A4 Substrates; Compounds used in a research, industrial, or household setting; Antiarrhythmic agents; Cyclopentane Monoterpenes; Cytochrome P-450 CYP2C9 Substrates; Agrochemicals; Bradycardia-Causing Agents; Toxic Actions; Ectoparasiticides, Incl. Scabicides, Insecticides and Repellents" CC(C)=CC1C(C(=O)OC2CC(=O)C(CC=C)=C2C)C1(C)C 2024 347829312 Bioallethrin CHEMBL1872535 19338 DB15102 Pemigatinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 32315352 "Liu PCC, Koblish H, Wu L, Bowman K, Diamond S, DiMatteo D, Zhang Y, Hansbury M, Rupar M, Wen X, Collier P, Feldman P, Klabe R, Burke KA, Soloviev M, Gardiner C, He X, Volgina A, Covington M, Ruggeri B, Wynn R, Burn TC, Scherle P, Yeleswaram S, Yao W, Huber R, Hollis G: INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. PLoS One. 2020 Apr 21;15(4):e0231877. doi: 10.1371/journal.pone.0231877. eCollection 2020." Approved; Investigational "OCT2 Inhibitors; Cytochrome P-450 CYP3A Substrates; Receptor, Fibroblast Growth Factor, Type 1, antagonists & inhibitors; MATE 1 Inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 Substrates; Oxazines; P-glycoprotein substrates; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; P-glycoprotein inhibitors; Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors; Fibroblast Growth Factor 2, antagonists & inhibitors; MATE inhibitors; Receptors, Fibroblast Growth Factor, antagonists & inhibitors; Cytochrome P-450 CYP3A4 Substrates; Antineoplastic and Immunomodulating Agents; Receptor, Fibroblast Growth Factor, Type 2, antagonists & inhibitors" CCN1C(=O)N(CC2=CN=C3NC(CN4CCOCC4)=CC3=C12)C1=C(F)C(OC)=CC(OC)=C1F 23643 Pemigatinib CHEMBL4297522 2359268 DB15149 Futibatinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor 32973082 "Sootome H, Fujita H, Ito K, Ochiiwa H, Fujioka Y, Ito K, Miura A, Sagara T, Ito S, Ohsawa H, Otsuki S, Funabashi K, Yashiro M, Matsuo K, Yonekura K, Hirai H: Futibatinib Is a Novel Irreversible FGFR 1-4 Inhibitor That Shows Selective Antitumor Activity against FGFR-Deregulated Tumors. Cancer Res. 2020 Nov 15;80(22):4986-4997. doi: 10.1158/0008-5472.CAN-19-2568. Epub 2020 Sep 24." Approved; Investigational BCRP/ABCG2 Substrates; Kinase Inhibitor; P-glycoprotein inhibitors; Antineoplastic and Immunomodulating Agents; Cytochrome P-450 CYP2D6 Substrates; Fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitors; Cytochrome P-450 CYP2C9 Substrates; Cytochrome P-450 Substrates; Cytochrome P-450 CYP3A Substrates; Cytochrome P-450 CYP3A4 Substrates; P-glycoprotein substrates; Antineoplastic Agents; Protein Kinase Inhibitors COC1=CC(=CC(OC)=C1)C#CC1=NN([C@H]2CCN(C2)C(=O)C=C)C2=C1C(N)=NC=N2 PA166293381 Futibatinib CHEMBL3701238 2628190 DB15685 Selpercatinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor Approved; Investigational QTc Prolonging Agents; Cytochrome P-450 CYP3A Substrates; MATE 1 Inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A Inhibitors; P-glycoprotein substrates; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; P-glycoprotein inhibitors; Hepatotoxic Agents; MATE inhibitors; Rearranged during Transfection (RET) Inhibitors; Tyrosine Kinase Inhibitors; Agents that produce hypertension; Cytochrome P-450 CYP3A4 Substrates; Antineoplastic and Immunomodulating Agents COC1=NC=C(CN2C3CC2CN(C3)C2=CC=C(C=N2)C2=CC(OCC(C)(C)O)=CN3N=CC(C#N)=C23)C=C1 23604 Selpercatinib CHEMBL4559134 2370147 DB15822 Pralsetinib BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor Approved; Investigational OATP1B1/SLCO1B1 Inhibitors; Cytochrome P-450 CYP3A Substrates; OAT1/SLC22A6 inhibitors; Cytochrome P-450 CYP3A5 Inhibitors; MATE 1 Inhibitors; Protein Kinase Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors; Cytochrome P-450 Enzyme Inducers; BCRP/ABCG2 Inhibitors; Cytochrome P-450 Substrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 CYP2C8 Inhibitors (strength unknown); Cytochrome P-450 CYP3A4 Inducers (strength unknown); Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 CYP2C9 Inducers (strength unknown); Cytochrome P-450 CYP3A4 Inducers; P-glycoprotein substrates; Cytochrome P-450 CYP2C9 Inhibitors; Cytochrome P-450 CYP3A4 Inhibitors; Antineoplastic Agents; BCRP/ABCG2 Substrates; Kinase Inhibitor; Cytochrome P-450 CYP2C8 Inducers; P-glycoprotein inhibitors; OATP1B3 inhibitors; Cytochrome P-450 CYP2D6 Substrates; Cytochrome P-450 CYP3A4 Inhibitors (strength unknown); Cytochrome P-450 CYP3A5 Inducers; Cytochrome P-450 CYP2C9 Inhibitors (strength unknown); MATE inhibitors; Rearranged during Transfection (RET) Inhibitors; Cytochrome P-450 CYP3A4 Substrates; Cytochrome P-450 CYP3A5 Inhibitors (strength unknown); Cytochrome P-450 CYP2C8 Inducers (strength unknown); Antineoplastic and Immunomodulating Agents; MATE 2 Inhibitors; BSEP/ABCB11 Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP2C9 Inducers; Cytochrome P-450 CYP3A5 Inducers (strength unknown); Cytochrome P-450 CYP1A2 Substrates CO[C@@]1(CC[C@@H](CC1)C1=NC(NC2=NNC(C)=C2)=CC(C)=N1)C(=O)N[C@@H](C)C1=CC=C(N=C1)N1C=C(F)C=N1 23611 Pralsetinib CHEMBL4582651 2394936 DB17587 KIN-3248 BE0000748 FGFR2 P21802 FGFR2_HUMAN inhibitor "Franovic A, Mohan A, Uryu S, Wu Q, Jiang P, Miller N, Tyhonas J, Timple N, Severson P, Kania R, Murphy E, Bardeesy N, Martin E.: Activity of KIN-3248, a next-generation pan-FGFR inhibitor, against acquired FGFR-gatekeeper and molecular-brake drug resistance mutations J Clin Oncol. 2022 Feb 01;40(suppl 4):461-461." Investigational